In conclusion, anthelminthics as cancer drugs seem to lack specificity for molecular targets and
lack safety profiles for systemic application in large part, such failing to fulfill the basic criteria for successful repurposing in oncology [3].
[22] The potential of synergies arising from these different mechanisms of action, the
safety and
lack of dose - limiting toxicities of the intralesional therapies, and the nonoverlapping toxicity
profiles of the contemplated combinations, offer an attractive rationale.